{
  "pmcid": "PMC3548984",
  "pmid": "23213055",
  "title": "CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8",
  "overall_score": 0.4054206776536173,
  "num_benchmarks": 3,
  "benchmarks": {
    "drug_annotations": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 35,
        "items": [
          {
            "variant": "CYP2D6*3",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2D6*3",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "In Arm A (5 years tamoxifen), CYP2D6 poor metabolizers with 2 null alleles (PM/PM) had a significantly higher odds of a disease event (recurrence, contralateral breast cancer, second non-breast cancer, or death) compared with extensive metabolizers (EM/EM): OR=2.45, 95% CI: 1.05\u20135.73, p=0.04.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Associated with increased response to tamoxifen in terms of higher odds of a disease event in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "\u201cGenotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.\u201d",
                "\u201cIn Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05\u20135.73, p=0.04) and women with one poor allele (PM/IM or PM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07) had a higher likelihood of an event than women with two extensive alleles (EM/EM).\u201d",
                "\u201cAmong the post-menopausal women with ER positive breast cancer enrolled on ABCSG 8 who were randomized to 5 years of tamoxifen (Arm A), there was a significantly higher odds of a disease event for those with CYP2D6 PM/PM phenotype relative to those with the CYP2D6 EM/EM phenotype, but this was not observed in patients treated with anastrozole following tamoxifen (Arm B).\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*4",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2D6*4",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "In Arm A (5 years tamoxifen), CYP2D6 poor metabolizers with 2 null alleles (PM/PM) had a significantly higher odds of a disease event (recurrence, contralateral breast cancer, second non-breast cancer, or death) compared with extensive metabolizers (EM/EM): OR=2.45, 95% CI: 1.05\u20135.73, p=0.04.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Associated with increased response to tamoxifen in terms of higher odds of a disease event in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "\u201cGenotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.\u201d",
                "\u201cIn Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05\u20135.73, p=0.04) and women with one poor allele (PM/IM or PM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07) had a higher likelihood of an event than women with two extensive alleles (EM/EM).\u201d",
                "\u201cAmong the post-menopausal women with ER positive breast cancer enrolled on ABCSG 8 who were randomized to 5 years of tamoxifen (Arm A), there was a significantly higher odds of a disease event for those with CYP2D6 PM/PM phenotype relative to those with the CYP2D6 EM/EM phenotype, but this was not observed in patients treated with anastrozole following tamoxifen (Arm B).\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*6",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2D6*6",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "In Arm A (5 years tamoxifen), CYP2D6 poor metabolizers with 2 null alleles (PM/PM) had a significantly higher odds of a disease event (recurrence, contralateral breast cancer, second non-breast cancer, or death) compared with extensive metabolizers (EM/EM): OR=2.45, 95% CI: 1.05\u20135.73, p=0.04.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Associated with increased response to tamoxifen in terms of higher odds of a disease event in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "\u201cGenotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.\u201d",
                "\u201cIn Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05\u20135.73, p=0.04) and women with one poor allele (PM/IM or PM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07) had a higher likelihood of an event than women with two extensive alleles (EM/EM).\u201d",
                "\u201cAmong the post-menopausal women with ER positive breast cancer enrolled on ABCSG 8 who were randomized to 5 years of tamoxifen (Arm A), there was a significantly higher odds of a disease event for those with CYP2D6 PM/PM phenotype relative to those with the CYP2D6 EM/EM phenotype, but this was not observed in patients treated with anastrozole following tamoxifen (Arm B).\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*10",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2D6*10",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "In Arm A (5 years tamoxifen), CYP2D6 poor metabolizers with 2 null alleles (PM/PM) had a significantly higher odds of a disease event (recurrence, contralateral breast cancer, second non-breast cancer, or death) compared with extensive metabolizers (EM/EM): OR=2.45, 95% CI: 1.05\u20135.73, p=0.04.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Associated with increased response to tamoxifen in terms of higher odds of a disease event in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "\u201cGenotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.\u201d",
                "\u201cIn Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05\u20135.73, p=0.04) and women with one poor allele (PM/IM or PM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07) had a higher likelihood of an event than women with two extensive alleles (EM/EM).\u201d",
                "\u201cAmong the post-menopausal women with ER positive breast cancer enrolled on ABCSG 8 who were randomized to 5 years of tamoxifen (Arm A), there was a significantly higher odds of a disease event for those with CYP2D6 PM/PM phenotype relative to those with the CYP2D6 EM/EM phenotype, but this was not observed in patients treated with anastrozole following tamoxifen (Arm B).\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*41",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2D6*41",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "yes",
              "Notes": "In Arm A (5 years tamoxifen), CYP2D6 poor metabolizers with 2 null alleles (PM/PM) had a significantly higher odds of a disease event (recurrence, contralateral breast cancer, second non-breast cancer, or death) compared with extensive metabolizers (EM/EM): OR=2.45, 95% CI: 1.05\u20135.73, p=0.04.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Associated with increased response to tamoxifen in terms of higher odds of a disease event in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "\u201cGenotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.\u201d",
                "\u201cIn Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05\u20135.73, p=0.04) and women with one poor allele (PM/IM or PM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07) had a higher likelihood of an event than women with two extensive alleles (EM/EM).\u201d",
                "\u201cAmong the post-menopausal women with ER positive breast cancer enrolled on ABCSG 8 who were randomized to 5 years of tamoxifen (Arm A), there was a significantly higher odds of a disease event for those with CYP2D6 PM/PM phenotype relative to those with the CYP2D6 EM/EM phenotype, but this was not observed in patients treated with anastrozole following tamoxifen (Arm B).\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*3",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "CYP2D6*3",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In Arm A (5 years tamoxifen), women with one poor allele (PM/IM or PM/EM) had a non-significant trend toward higher odds of a disease event compared with EM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07.",
              "Sentence": "CYP2D6 phenotypes PM/IM + PM/EM Are Not associated with increased response to tamoxifen in terms of higher odds of a disease event in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/IM + PM/EM",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "\"In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05\u20135.73, p=0.04) and women with one poor allele (PM/IM or PM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07) had a higher likelihood of an event than women with two extensive alleles (EM/EM).\"",
                "\"In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM (Table 5). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event.\"",
                "\"Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*4",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "CYP2D6*4",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In Arm A (5 years tamoxifen), women with one poor allele (PM/IM or PM/EM) had a non-significant trend toward higher odds of a disease event compared with EM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07.",
              "Sentence": "CYP2D6 phenotypes PM/IM + PM/EM Are Not associated with increased response to tamoxifen in terms of higher odds of a disease event in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/IM + PM/EM",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "\"In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05\u20135.73, p=0.04) and women with one poor allele (PM/IM or PM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07) had a higher likelihood of an event than women with two extensive alleles (EM/EM).\"",
                "\"In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM (Table 5). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event.\"",
                "\"Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*6",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "CYP2D6*6",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In Arm A (5 years tamoxifen), women with one poor allele (PM/IM or PM/EM) had a non-significant trend toward higher odds of a disease event compared with EM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07.",
              "Sentence": "CYP2D6 phenotypes PM/IM + PM/EM Are Not associated with increased response to tamoxifen in terms of higher odds of a disease event in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/IM + PM/EM",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "\"In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05\u20135.73, p=0.04) and women with one poor allele (PM/IM or PM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07) had a higher likelihood of an event than women with two extensive alleles (EM/EM).\"",
                "\"In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM (Table 5). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event.\"",
                "\"Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*10",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "CYP2D6*10",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In Arm A (5 years tamoxifen), women with one poor allele (PM/IM or PM/EM) had a non-significant trend toward higher odds of a disease event compared with EM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07.",
              "Sentence": "CYP2D6 phenotypes PM/IM + PM/EM Are Not associated with increased response to tamoxifen in terms of higher odds of a disease event in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/IM + PM/EM",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "\"In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05\u20135.73, p=0.04) and women with one poor allele (PM/IM or PM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07) had a higher likelihood of an event than women with two extensive alleles (EM/EM).\"",
                "\"In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM (Table 5). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event.\"",
                "\"Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*41",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "CYP2D6*41",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In Arm A (5 years tamoxifen), women with one poor allele (PM/IM or PM/EM) had a non-significant trend toward higher odds of a disease event compared with EM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07.",
              "Sentence": "CYP2D6 phenotypes PM/IM + PM/EM Are Not associated with increased response to tamoxifen in terms of higher odds of a disease event in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/IM + PM/EM",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "\"In Arm A during the first 5 years of therapy, women with 2 poor alleles (PM/PM: OR=2.45, 95% CI: 1.05\u20135.73, p=0.04) and women with one poor allele (PM/IM or PM/EM: OR=1.67, 95% CI: 0.95\u20132.93, p=0.07) had a higher likelihood of an event than women with two extensive alleles (EM/EM).\"",
                "\"In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM (Table 5). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event.\"",
                "\"Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*3",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "CYP2D6*3",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In Arm A (5 years tamoxifen), women classified as EM/IM or IM/IM did not have increased odds of a disease event compared with EM/EM: OR=1.23, 95% CI: 0.58\u20132.61, p=0.60.",
              "Sentence": "CYP2D6 phenotypes EM/IM + IM/IM Are Not associated with increased response to tamoxifen in terms of higher odds of a disease event in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "EM/IM + IM/IM",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "\"CYP2D6 phenotype groups were defined as previously published (11) where \u2018extensive\u2019 metabolizers do not carry a null or reduced allele (EM/EM); those with one to two reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \u2018poor\u2019 metabolizers, those with 2 null alleles (PM/PM).\"",
                "\"In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM (Table 5). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event.\"",
                "\"Tamoxifen is a weak anti-estrogen with agonistic properties that is extensively metabolized into potent anti-estrogens, 4-hydroxy tamoxifen and endoxifen\u2026 Endoxifen is formed by the CYP2D6-mediated oxidation of n-desmethyl tamoxifen\u2026 Common genetic variations in CYP2D6 and/or drug-induced inhibition of CYP2D6 enzyme activity are associated with significant reductions in endoxifen concentrations in tamoxifen treated humans (6\u20138).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*4",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "CYP2D6*4",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In Arm A (5 years tamoxifen), women classified as EM/IM or IM/IM did not have increased odds of a disease event compared with EM/EM: OR=1.23, 95% CI: 0.58\u20132.61, p=0.60.",
              "Sentence": "CYP2D6 phenotypes EM/IM + IM/IM Are Not associated with increased response to tamoxifen in terms of higher odds of a disease event in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "EM/IM + IM/IM",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "\"CYP2D6 phenotype groups were defined as previously published (11) where \u2018extensive\u2019 metabolizers do not carry a null or reduced allele (EM/EM); those with one to two reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \u2018poor\u2019 metabolizers, those with 2 null alleles (PM/PM).\"",
                "\"In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM (Table 5). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event.\"",
                "\"Tamoxifen is a weak anti-estrogen with agonistic properties that is extensively metabolized into potent anti-estrogens, 4-hydroxy tamoxifen and endoxifen\u2026 Endoxifen is formed by the CYP2D6-mediated oxidation of n-desmethyl tamoxifen\u2026 Common genetic variations in CYP2D6 and/or drug-induced inhibition of CYP2D6 enzyme activity are associated with significant reductions in endoxifen concentrations in tamoxifen treated humans (6\u20138).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*6",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "CYP2D6*6",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In Arm A (5 years tamoxifen), women classified as EM/IM or IM/IM did not have increased odds of a disease event compared with EM/EM: OR=1.23, 95% CI: 0.58\u20132.61, p=0.60.",
              "Sentence": "CYP2D6 phenotypes EM/IM + IM/IM Are Not associated with increased response to tamoxifen in terms of higher odds of a disease event in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "EM/IM + IM/IM",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "\"CYP2D6 phenotype groups were defined as previously published (11) where \u2018extensive\u2019 metabolizers do not carry a null or reduced allele (EM/EM); those with one to two reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \u2018poor\u2019 metabolizers, those with 2 null alleles (PM/PM).\"",
                "\"In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM (Table 5). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event.\"",
                "\"Tamoxifen is a weak anti-estrogen with agonistic properties that is extensively metabolized into potent anti-estrogens, 4-hydroxy tamoxifen and endoxifen\u2026 Endoxifen is formed by the CYP2D6-mediated oxidation of n-desmethyl tamoxifen\u2026 Common genetic variations in CYP2D6 and/or drug-induced inhibition of CYP2D6 enzyme activity are associated with significant reductions in endoxifen concentrations in tamoxifen treated humans (6\u20138).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*10",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "CYP2D6*10",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In Arm A (5 years tamoxifen), women classified as EM/IM or IM/IM did not have increased odds of a disease event compared with EM/EM: OR=1.23, 95% CI: 0.58\u20132.61, p=0.60.",
              "Sentence": "CYP2D6 phenotypes EM/IM + IM/IM Are Not associated with increased response to tamoxifen in terms of higher odds of a disease event in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "EM/IM + IM/IM",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "\"CYP2D6 phenotype groups were defined as previously published (11) where \u2018extensive\u2019 metabolizers do not carry a null or reduced allele (EM/EM); those with one to two reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \u2018poor\u2019 metabolizers, those with 2 null alleles (PM/PM).\"",
                "\"In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM (Table 5). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event.\"",
                "\"Tamoxifen is a weak anti-estrogen with agonistic properties that is extensively metabolized into potent anti-estrogens, 4-hydroxy tamoxifen and endoxifen\u2026 Endoxifen is formed by the CYP2D6-mediated oxidation of n-desmethyl tamoxifen\u2026 Common genetic variations in CYP2D6 and/or drug-induced inhibition of CYP2D6 enzyme activity are associated with significant reductions in endoxifen concentrations in tamoxifen treated humans (6\u20138).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*41",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "CYP2D6*41",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In Arm A (5 years tamoxifen), women classified as EM/IM or IM/IM did not have increased odds of a disease event compared with EM/EM: OR=1.23, 95% CI: 0.58\u20132.61, p=0.60.",
              "Sentence": "CYP2D6 phenotypes EM/IM + IM/IM Are Not associated with increased response to tamoxifen in terms of higher odds of a disease event in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "EM/IM + IM/IM",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "\"CYP2D6 phenotype groups were defined as previously published (11) where \u2018extensive\u2019 metabolizers do not carry a null or reduced allele (EM/EM); those with one to two reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \u2018poor\u2019 metabolizers, those with 2 null alleles (PM/PM).\"",
                "\"In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM (Table 5). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event.\"",
                "\"Tamoxifen is a weak anti-estrogen with agonistic properties that is extensively metabolized into potent anti-estrogens, 4-hydroxy tamoxifen and endoxifen\u2026 Endoxifen is formed by the CYP2D6-mediated oxidation of n-desmethyl tamoxifen\u2026 Common genetic variations in CYP2D6 and/or drug-induced inhibition of CYP2D6 enzyme activity are associated with significant reductions in endoxifen concentrations in tamoxifen treated humans (6\u20138).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*3",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2D6*3",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In the first 2 years of tamoxifen when all patients received tamoxifen, PM/PM showed a non-significant higher odds of a disease event relative to EM/EM: Arm A OR=2.54, p=0.25; Arm B OR=2.60, p=0.46.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Not associated with increased response to tamoxifen in terms of higher odds of a disease event during the first 2 years of therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.",
                "Conditional logistic regression modeling (CLRM) for matched triplets and pairs was used to examine whether the odds of a disease event differed with respect to CYP2D6 genotype in the following situations: 1) the first 5 years of treatment, for each arm separately 2) years 3\u20135 of treatment, for each arm separately, 3) in the first 2 years of treatment, (when all patients were assigned tamoxifen).",
                "There were a limited number of events during years 1\u20132 (Table 3); however, a similar non-significant higher odds of a disease event was observed for PM/PM relative to EM/EM in the first 2 years of tamoxifen for both arms: Arm A: OR = 2.54, p = 0.25 and Arm B: OR = 2.60, p = 0.46."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*4",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2D6*4",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In the first 2 years of tamoxifen when all patients received tamoxifen, PM/PM showed a non-significant higher odds of a disease event relative to EM/EM: Arm A OR=2.54, p=0.25; Arm B OR=2.60, p=0.46.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Not associated with increased response to tamoxifen in terms of higher odds of a disease event during the first 2 years of therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.",
                "Conditional logistic regression modeling (CLRM) for matched triplets and pairs was used to examine whether the odds of a disease event differed with respect to CYP2D6 genotype in the following situations: 1) the first 5 years of treatment, for each arm separately 2) years 3\u20135 of treatment, for each arm separately, 3) in the first 2 years of treatment, (when all patients were assigned tamoxifen).",
                "There were a limited number of events during years 1\u20132 (Table 3); however, a similar non-significant higher odds of a disease event was observed for PM/PM relative to EM/EM in the first 2 years of tamoxifen for both arms: Arm A: OR = 2.54, p = 0.25 and Arm B: OR = 2.60, p = 0.46."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*6",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2D6*6",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In the first 2 years of tamoxifen when all patients received tamoxifen, PM/PM showed a non-significant higher odds of a disease event relative to EM/EM: Arm A OR=2.54, p=0.25; Arm B OR=2.60, p=0.46.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Not associated with increased response to tamoxifen in terms of higher odds of a disease event during the first 2 years of therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.",
                "Conditional logistic regression modeling (CLRM) for matched triplets and pairs was used to examine whether the odds of a disease event differed with respect to CYP2D6 genotype in the following situations: 1) the first 5 years of treatment, for each arm separately 2) years 3\u20135 of treatment, for each arm separately, 3) in the first 2 years of treatment, (when all patients were assigned tamoxifen).",
                "There were a limited number of events during years 1\u20132 (Table 3); however, a similar non-significant higher odds of a disease event was observed for PM/PM relative to EM/EM in the first 2 years of tamoxifen for both arms: Arm A: OR = 2.54, p = 0.25 and Arm B: OR = 2.60, p = 0.46."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*10",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2D6*10",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In the first 2 years of tamoxifen when all patients received tamoxifen, PM/PM showed a non-significant higher odds of a disease event relative to EM/EM: Arm A OR=2.54, p=0.25; Arm B OR=2.60, p=0.46.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Not associated with increased response to tamoxifen in terms of higher odds of a disease event during the first 2 years of therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.",
                "Conditional logistic regression modeling (CLRM) for matched triplets and pairs was used to examine whether the odds of a disease event differed with respect to CYP2D6 genotype in the following situations: 1) the first 5 years of treatment, for each arm separately 2) years 3\u20135 of treatment, for each arm separately, 3) in the first 2 years of treatment, (when all patients were assigned tamoxifen).",
                "There were a limited number of events during years 1\u20132 (Table 3); however, a similar non-significant higher odds of a disease event was observed for PM/PM relative to EM/EM in the first 2 years of tamoxifen for both arms: Arm A: OR = 2.54, p = 0.25 and Arm B: OR = 2.60, p = 0.46."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*41",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2D6*41",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In the first 2 years of tamoxifen when all patients received tamoxifen, PM/PM showed a non-significant higher odds of a disease event relative to EM/EM: Arm A OR=2.54, p=0.25; Arm B OR=2.60, p=0.46.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Not associated with increased response to tamoxifen in terms of higher odds of a disease event during the first 2 years of therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "Genotyping was performed for alleles associated with no (PM; *3, *4, *6); reduced (IM; *10, and *41); and extensive (EM: absence of these alleles) CYP2D6 metabolism.",
                "Conditional logistic regression modeling (CLRM) for matched triplets and pairs was used to examine whether the odds of a disease event differed with respect to CYP2D6 genotype in the following situations: 1) the first 5 years of treatment, for each arm separately 2) years 3\u20135 of treatment, for each arm separately, 3) in the first 2 years of treatment, (when all patients were assigned tamoxifen).",
                "There were a limited number of events during years 1\u20132 (Table 3); however, a similar non-significant higher odds of a disease event was observed for PM/PM relative to EM/EM in the first 2 years of tamoxifen for both arms: Arm A: OR = 2.54, p = 0.25 and Arm B: OR = 2.60, p = 0.46."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*3",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "CYP2D6*3",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "During years 3\u20135 for women in Arm A who remained on tamoxifen, PM/PM had a non-significant trend toward increased odds of a disease event relative to EM/EM: OR=2.40, 95% CI: 0.86\u20136.66, p=0.09.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Not associated with increased response to tamoxifen in terms of higher odds of a disease event during years 3\u20135 of therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "In years 3\u20135 when patients remained on tamoxifen (Arm A) or switched to anastrozole (Arm B), PM/PM tended towards a higher likelihood of a disease event relative to EM/EM (OR= 2.40, 95% CI: 0.86\u20136.66, p=0.09) among women on Arm A but not among women on Arm B (OR= 0.28; 95% CI: 0.03\u20132.30).",
                "During years 3\u20135, for women on Arm A who remained event free during the first 2 years of tamoxifen therapy, PM/PM (OR 2.40, 95% CI: 0.86 to 6.66, p = 0.09) and IM/PM or EM/PM (OR 1.70, 95% CI: 0.91\u20133.17, p=0.09) had a trend towards an increased odds of a disease event relative to EM/EM."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*4",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "CYP2D6*4",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "During years 3\u20135 for women in Arm A who remained on tamoxifen, PM/PM had a non-significant trend toward increased odds of a disease event relative to EM/EM: OR=2.40, 95% CI: 0.86\u20136.66, p=0.09.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Not associated with increased response to tamoxifen in terms of higher odds of a disease event during years 3\u20135 of therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "In years 3\u20135 when patients remained on tamoxifen (Arm A) or switched to anastrozole (Arm B), PM/PM tended towards a higher likelihood of a disease event relative to EM/EM (OR= 2.40, 95% CI: 0.86\u20136.66, p=0.09) among women on Arm A but not among women on Arm B (OR= 0.28; 95% CI: 0.03\u20132.30).",
                "During years 3\u20135, for women on Arm A who remained event free during the first 2 years of tamoxifen therapy, PM/PM (OR 2.40, 95% CI: 0.86 to 6.66, p = 0.09) and IM/PM or EM/PM (OR 1.70, 95% CI: 0.91\u20133.17, p=0.09) had a trend towards an increased odds of a disease event relative to EM/EM."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*6",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "CYP2D6*6",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "During years 3\u20135 for women in Arm A who remained on tamoxifen, PM/PM had a non-significant trend toward increased odds of a disease event relative to EM/EM: OR=2.40, 95% CI: 0.86\u20136.66, p=0.09.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Not associated with increased response to tamoxifen in terms of higher odds of a disease event during years 3\u20135 of therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "In years 3\u20135 when patients remained on tamoxifen (Arm A) or switched to anastrozole (Arm B), PM/PM tended towards a higher likelihood of a disease event relative to EM/EM (OR= 2.40, 95% CI: 0.86\u20136.66, p=0.09) among women on Arm A but not among women on Arm B (OR= 0.28; 95% CI: 0.03\u20132.30).",
                "During years 3\u20135, for women on Arm A who remained event free during the first 2 years of tamoxifen therapy, PM/PM (OR 2.40, 95% CI: 0.86 to 6.66, p = 0.09) and IM/PM or EM/PM (OR 1.70, 95% CI: 0.91\u20133.17, p=0.09) had a trend towards an increased odds of a disease event relative to EM/EM."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*10",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "CYP2D6*10",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "During years 3\u20135 for women in Arm A who remained on tamoxifen, PM/PM had a non-significant trend toward increased odds of a disease event relative to EM/EM: OR=2.40, 95% CI: 0.86\u20136.66, p=0.09.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Not associated with increased response to tamoxifen in terms of higher odds of a disease event during years 3\u20135 of therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "In years 3\u20135 when patients remained on tamoxifen (Arm A) or switched to anastrozole (Arm B), PM/PM tended towards a higher likelihood of a disease event relative to EM/EM (OR= 2.40, 95% CI: 0.86\u20136.66, p=0.09) among women on Arm A but not among women on Arm B (OR= 0.28; 95% CI: 0.03\u20132.30).",
                "During years 3\u20135, for women on Arm A who remained event free during the first 2 years of tamoxifen therapy, PM/PM (OR 2.40, 95% CI: 0.86 to 6.66, p = 0.09) and IM/PM or EM/PM (OR 1.70, 95% CI: 0.91\u20133.17, p=0.09) had a trend towards an increased odds of a disease event relative to EM/EM."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*41",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "CYP2D6*41",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "During years 3\u20135 for women in Arm A who remained on tamoxifen, PM/PM had a non-significant trend toward increased odds of a disease event relative to EM/EM: OR=2.40, 95% CI: 0.86\u20136.66, p=0.09.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Not associated with increased response to tamoxifen in terms of higher odds of a disease event during years 3\u20135 of therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "In years 3\u20135 when patients remained on tamoxifen (Arm A) or switched to anastrozole (Arm B), PM/PM tended towards a higher likelihood of a disease event relative to EM/EM (OR= 2.40, 95% CI: 0.86\u20136.66, p=0.09) among women on Arm A but not among women on Arm B (OR= 0.28; 95% CI: 0.03\u20132.30).",
                "During years 3\u20135, for women on Arm A who remained event free during the first 2 years of tamoxifen therapy, PM/PM (OR 2.40, 95% CI: 0.86 to 6.66, p = 0.09) and IM/PM or EM/PM (OR 1.70, 95% CI: 0.91\u20133.17, p=0.09) had a trend towards an increased odds of a disease event relative to EM/EM."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*3",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "CYP2D6*3",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "During years 3\u20135 for women in Arm A on continued tamoxifen, patients with at least one poor allele (IM/PM or EM/PM) had a non-significant trend towards increased odds of a disease event relative to EM/EM: OR=1.70, 95% CI: 0.91\u20133.17, p=0.09.",
              "Sentence": "CYP2D6 phenotypes EM/PM + PM/IM Are Not associated with increased response to tamoxifen in terms of higher odds of a disease event during years 3\u20135 of therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "EM/PM + PM/IM",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "During years 3\u20135, for women on Arm A who remained event free during the first 2 years of tamoxifen therapy, PM/PM (OR 2.40, 95% CI: 0.86 to 6.66, p = 0.09) and IM/PM or EM/PM (OR 1.70, 95% CI: 0.91\u20133.17, p=0.09) had a trend towards an increased odds of a disease event relative to EM/EM.",
                "In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM ([Table 5](#T5)). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*4",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "CYP2D6*4",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "During years 3\u20135 for women in Arm A on continued tamoxifen, patients with at least one poor allele (IM/PM or EM/PM) had a non-significant trend towards increased odds of a disease event relative to EM/EM: OR=1.70, 95% CI: 0.91\u20133.17, p=0.09.",
              "Sentence": "CYP2D6 phenotypes EM/PM + PM/IM Are Not associated with increased response to tamoxifen in terms of higher odds of a disease event during years 3\u20135 of therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "EM/PM + PM/IM",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "During years 3\u20135, for women on Arm A who remained event free during the first 2 years of tamoxifen therapy, PM/PM (OR 2.40, 95% CI: 0.86 to 6.66, p = 0.09) and IM/PM or EM/PM (OR 1.70, 95% CI: 0.91\u20133.17, p=0.09) had a trend towards an increased odds of a disease event relative to EM/EM.",
                "In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM ([Table 5](#T5)). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*6",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "CYP2D6*6",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "During years 3\u20135 for women in Arm A on continued tamoxifen, patients with at least one poor allele (IM/PM or EM/PM) had a non-significant trend towards increased odds of a disease event relative to EM/EM: OR=1.70, 95% CI: 0.91\u20133.17, p=0.09.",
              "Sentence": "CYP2D6 phenotypes EM/PM + PM/IM Are Not associated with increased response to tamoxifen in terms of higher odds of a disease event during years 3\u20135 of therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "EM/PM + PM/IM",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "During years 3\u20135, for women on Arm A who remained event free during the first 2 years of tamoxifen therapy, PM/PM (OR 2.40, 95% CI: 0.86 to 6.66, p = 0.09) and IM/PM or EM/PM (OR 1.70, 95% CI: 0.91\u20133.17, p=0.09) had a trend towards an increased odds of a disease event relative to EM/EM.",
                "In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM ([Table 5](#T5)). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*10",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "CYP2D6*10",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "During years 3\u20135 for women in Arm A on continued tamoxifen, patients with at least one poor allele (IM/PM or EM/PM) had a non-significant trend towards increased odds of a disease event relative to EM/EM: OR=1.70, 95% CI: 0.91\u20133.17, p=0.09.",
              "Sentence": "CYP2D6 phenotypes EM/PM + PM/IM Are Not associated with increased response to tamoxifen in terms of higher odds of a disease event during years 3\u20135 of therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "EM/PM + PM/IM",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "During years 3\u20135, for women on Arm A who remained event free during the first 2 years of tamoxifen therapy, PM/PM (OR 2.40, 95% CI: 0.86 to 6.66, p = 0.09) and IM/PM or EM/PM (OR 1.70, 95% CI: 0.91\u20133.17, p=0.09) had a trend towards an increased odds of a disease event relative to EM/EM.",
                "In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM ([Table 5](#T5)). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*41",
            "gene": "CYP2D6",
            "drug": "tamoxifen",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "CYP2D6*41",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "During years 3\u20135 for women in Arm A on continued tamoxifen, patients with at least one poor allele (IM/PM or EM/PM) had a non-significant trend towards increased odds of a disease event relative to EM/EM: OR=1.70, 95% CI: 0.91\u20133.17, p=0.09.",
              "Sentence": "CYP2D6 phenotypes EM/PM + PM/IM Are Not associated with increased response to tamoxifen in terms of higher odds of a disease event during years 3\u20135 of therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "EM/PM + PM/IM",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "During years 3\u20135, for women on Arm A who remained event free during the first 2 years of tamoxifen therapy, PM/PM (OR 2.40, 95% CI: 0.86 to 6.66, p = 0.09) and IM/PM or EM/PM (OR 1.70, 95% CI: 0.91\u20133.17, p=0.09) had a trend towards an increased odds of a disease event relative to EM/EM.",
                "In Arm A during the 5 years of tamoxifen treatment, PM/PM (OR 2.45, 95% CI: 1.05\u20135.73; p=0.04) had a higher odds of a disease event relative to EM/EM ([Table 5](#T5)). There was also a trend for patients classified as IM/PM or EM/PM relative to EM/EM (OR 1.67, 95% CI: 0.95\u20132.93, p=0.07) but not in patients classified as EM/IM or IM/IM relative to EM/EM (OR 1.23, 95% CI: 0.58\u20132.61, p=0.60) to have a higher odds of a disease event."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "tamoxifen",
                "drug_id": "PA451581",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*3",
            "gene": "CYP2D6",
            "drug": "tamoxifen, anastrozole",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "CYP2D6*3",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen, anastrozole",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In Arm B (2 years tamoxifen followed by 3 years anastrozole), no significant association was found between CYP2D6 phenotype and the likelihood of a disease event during the 5 years of treatment. Specifically, PM/PM vs EM/EM: OR=0.60, 95% CI: 0.15\u20132.37, p=0.47; EM/PM + PM/IM vs EM/EM: OR=0.76, 95% CI: 0.43\u20131.31, p=0.32; EM/IM + IM/IM vs EM/EM: OR=1.02, 95% CI: 0.52\u20132.01, p=0.96.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Not associated with response to tamoxifen and anastrozole in terms of odds of a disease event over 5 years of sequential therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "and",
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "Conversely in Arm B, no significant association was found between *CYP2D6* genotype and the likelihood of a disease event during the 5 years of treatment.",
                "|   | Tamoxifen only (Arm A) |  | Tamoxifen followed by anastrozole (Arm B) |  |\n| --- | --- | --- | --- | --- |\n|   | Odds Ratio (95% CI) | p-value | Odds Ratio (95% CI) | p-value |\n| PM/PM relative to EM/EM | 2.45 (1.05, 5.73) | 0.04 | 0.60 (0.15, 2.37) | 0.47 |\n| EM/PM and PM/IM relative to EM/EM | 1.67 (0.95, 2.93) | 0.07 | 0.76 (0.43, 1.31) | 0.32 |\n| EM/IM and IM/IM relative to EM/EM | 1.23 (0.58, 2.61) | 0.60 | 1.02 (0.52, 2.01) | 0.96 |",
                "For ABCSG 8 patients randomized to 2 years of tamoxifen followed by 3 years of anastrozole (Arm B), *CYP2D6* genotype was not associated with the odds of a disease event."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "anastrozole",
                "drug_id": "PA448432",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*4",
            "gene": "CYP2D6",
            "drug": "tamoxifen, anastrozole",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "CYP2D6*4",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen, anastrozole",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In Arm B (2 years tamoxifen followed by 3 years anastrozole), no significant association was found between CYP2D6 phenotype and the likelihood of a disease event during the 5 years of treatment. Specifically, PM/PM vs EM/EM: OR=0.60, 95% CI: 0.15\u20132.37, p=0.47; EM/PM + PM/IM vs EM/EM: OR=0.76, 95% CI: 0.43\u20131.31, p=0.32; EM/IM + IM/IM vs EM/EM: OR=1.02, 95% CI: 0.52\u20132.01, p=0.96.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Not associated with response to tamoxifen and anastrozole in terms of odds of a disease event over 5 years of sequential therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "and",
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "Conversely in Arm B, no significant association was found between *CYP2D6* genotype and the likelihood of a disease event during the 5 years of treatment.",
                "|   | Tamoxifen only (Arm A) |  | Tamoxifen followed by anastrozole (Arm B) |  |\n| --- | --- | --- | --- | --- |\n|   | Odds Ratio (95% CI) | p-value | Odds Ratio (95% CI) | p-value |\n| PM/PM relative to EM/EM | 2.45 (1.05, 5.73) | 0.04 | 0.60 (0.15, 2.37) | 0.47 |\n| EM/PM and PM/IM relative to EM/EM | 1.67 (0.95, 2.93) | 0.07 | 0.76 (0.43, 1.31) | 0.32 |\n| EM/IM and IM/IM relative to EM/EM | 1.23 (0.58, 2.61) | 0.60 | 1.02 (0.52, 2.01) | 0.96 |",
                "For ABCSG 8 patients randomized to 2 years of tamoxifen followed by 3 years of anastrozole (Arm B), *CYP2D6* genotype was not associated with the odds of a disease event."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "anastrozole",
                "drug_id": "PA448432",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*6",
            "gene": "CYP2D6",
            "drug": "tamoxifen, anastrozole",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "CYP2D6*6",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen, anastrozole",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In Arm B (2 years tamoxifen followed by 3 years anastrozole), no significant association was found between CYP2D6 phenotype and the likelihood of a disease event during the 5 years of treatment. Specifically, PM/PM vs EM/EM: OR=0.60, 95% CI: 0.15\u20132.37, p=0.47; EM/PM + PM/IM vs EM/EM: OR=0.76, 95% CI: 0.43\u20131.31, p=0.32; EM/IM + IM/IM vs EM/EM: OR=1.02, 95% CI: 0.52\u20132.01, p=0.96.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Not associated with response to tamoxifen and anastrozole in terms of odds of a disease event over 5 years of sequential therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "and",
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "Conversely in Arm B, no significant association was found between *CYP2D6* genotype and the likelihood of a disease event during the 5 years of treatment.",
                "|   | Tamoxifen only (Arm A) |  | Tamoxifen followed by anastrozole (Arm B) |  |\n| --- | --- | --- | --- | --- |\n|   | Odds Ratio (95% CI) | p-value | Odds Ratio (95% CI) | p-value |\n| PM/PM relative to EM/EM | 2.45 (1.05, 5.73) | 0.04 | 0.60 (0.15, 2.37) | 0.47 |\n| EM/PM and PM/IM relative to EM/EM | 1.67 (0.95, 2.93) | 0.07 | 0.76 (0.43, 1.31) | 0.32 |\n| EM/IM and IM/IM relative to EM/EM | 1.23 (0.58, 2.61) | 0.60 | 1.02 (0.52, 2.01) | 0.96 |",
                "For ABCSG 8 patients randomized to 2 years of tamoxifen followed by 3 years of anastrozole (Arm B), *CYP2D6* genotype was not associated with the odds of a disease event."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "anastrozole",
                "drug_id": "PA448432",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*10",
            "gene": "CYP2D6",
            "drug": "tamoxifen, anastrozole",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "CYP2D6*10",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen, anastrozole",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In Arm B (2 years tamoxifen followed by 3 years anastrozole), no significant association was found between CYP2D6 phenotype and the likelihood of a disease event during the 5 years of treatment. Specifically, PM/PM vs EM/EM: OR=0.60, 95% CI: 0.15\u20132.37, p=0.47; EM/PM + PM/IM vs EM/EM: OR=0.76, 95% CI: 0.43\u20131.31, p=0.32; EM/IM + IM/IM vs EM/EM: OR=1.02, 95% CI: 0.52\u20132.01, p=0.96.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Not associated with response to tamoxifen and anastrozole in terms of odds of a disease event over 5 years of sequential therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "and",
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "Conversely in Arm B, no significant association was found between *CYP2D6* genotype and the likelihood of a disease event during the 5 years of treatment.",
                "|   | Tamoxifen only (Arm A) |  | Tamoxifen followed by anastrozole (Arm B) |  |\n| --- | --- | --- | --- | --- |\n|   | Odds Ratio (95% CI) | p-value | Odds Ratio (95% CI) | p-value |\n| PM/PM relative to EM/EM | 2.45 (1.05, 5.73) | 0.04 | 0.60 (0.15, 2.37) | 0.47 |\n| EM/PM and PM/IM relative to EM/EM | 1.67 (0.95, 2.93) | 0.07 | 0.76 (0.43, 1.31) | 0.32 |\n| EM/IM and IM/IM relative to EM/EM | 1.23 (0.58, 2.61) | 0.60 | 1.02 (0.52, 2.01) | 0.96 |",
                "For ABCSG 8 patients randomized to 2 years of tamoxifen followed by 3 years of anastrozole (Arm B), *CYP2D6* genotype was not associated with the odds of a disease event."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "anastrozole",
                "drug_id": "PA448432",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2D6*41",
            "gene": "CYP2D6",
            "drug": "tamoxifen, anastrozole",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "CYP2D6*41",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen, anastrozole",
              "PMID": 23213055,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In Arm B (2 years tamoxifen followed by 3 years anastrozole), no significant association was found between CYP2D6 phenotype and the likelihood of a disease event during the 5 years of treatment. Specifically, PM/PM vs EM/EM: OR=0.60, 95% CI: 0.15\u20132.37, p=0.47; EM/PM + PM/IM vs EM/EM: OR=0.76, 95% CI: 0.43\u20131.31, p=0.32; EM/IM + IM/IM vs EM/EM: OR=1.02, 95% CI: 0.52\u20132.01, p=0.96.",
              "Sentence": "CYP2D6 poor metabolizer phenotype PM/PM Is Not associated with response to tamoxifen and anastrozole in terms of odds of a disease event over 5 years of sequential therapy in patients with Disease:Breast Neoplasms as compared to CYP2D6 extensive metabolizer phenotype EM/EM.",
              "Alleles": "PM/PM",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": "and",
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "EM/EM",
              "Comparison Metabolizer types": "extensive metabolizer",
              "Citations": [
                "Conversely in Arm B, no significant association was found between *CYP2D6* genotype and the likelihood of a disease event during the 5 years of treatment.",
                "|   | Tamoxifen only (Arm A) |  | Tamoxifen followed by anastrozole (Arm B) |  |\n| --- | --- | --- | --- | --- |\n|   | Odds Ratio (95% CI) | p-value | Odds Ratio (95% CI) | p-value |\n| PM/PM relative to EM/EM | 2.45 (1.05, 5.73) | 0.04 | 0.60 (0.15, 2.37) | 0.47 |\n| EM/PM and PM/IM relative to EM/EM | 1.67 (0.95, 2.93) | 0.07 | 0.76 (0.43, 1.31) | 0.32 |\n| EM/IM and IM/IM relative to EM/EM | 1.23 (0.58, 2.61) | 0.60 | 1.02 (0.52, 2.01) | 0.96 |",
                "For ABCSG 8 patients randomized to 2 years of tamoxifen followed by 3 years of anastrozole (Arm B), *CYP2D6* genotype was not associated with the odds of a disease event."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10, CYP2D6*41",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "anastrozole",
                "drug_id": "PA448432",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          }
        ]
      }
    },
    "phenotype_annotations": {
      "score": 0.5956305851538976,
      "total_samples": 10,
      "ground_truth_annotations": {
        "count": 10,
        "matched_count": 7,
        "unmatched_count": 3,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.972666883468628,
            "annotation": {
              "Variant/Haplotypes": "CYP2D6*4",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "Phenotype Category": "Efficacy",
              "Alleles": "*3/*3 + *4/*4",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Efficacy:Recurrence",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*4",
                "prediction": "CYP2D6*4",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "tamoxifen",
                "prediction": "tamoxifen",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*3/*3 + *4/*4",
                "prediction": "*4",
                "score": 0.9529426097869873,
                "match_status": "match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Recurrence",
                "prediction": "Efficacy:Disease event",
                "score": 0.909725546836853,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "extensive metabolizer genotype (no null or reduced alleles)",
                "score": 0.864000678062439,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.9718982398509979,
            "annotation": {
              "Variant/Haplotypes": "CYP2D6*3",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "Phenotype Category": "Efficacy",
              "Alleles": "*3/*3 + *4/*4",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Efficacy:Recurrence",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*3",
                "prediction": "CYP2D6*3",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "tamoxifen",
                "prediction": "tamoxifen",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*3/*3 + *4/*4",
                "prediction": "*3",
                "score": 0.9452561736106873,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Recurrence",
                "prediction": "Efficacy:Disease event",
                "score": 0.909725546836853,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "extensive metabolizer genotype (no null or reduced alleles)",
                "score": 0.864000678062439,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8693049550056458,
            "annotation": {
              "Variant/Haplotypes": "CYP2D6*6",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "Phenotype Category": "Efficacy",
              "Alleles": "*1/*3 + *1/*4 + *1/*6",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Phenotype": "Efficacy:Recurrence",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*6",
                "prediction": "CYP2D6*6",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "tamoxifen",
                "prediction": "tamoxifen",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*1/*3 + *1/*4 + *1/*6",
                "prediction": "*6",
                "score": 0.9193233251571655,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Not associated with",
                "prediction": "Associated with",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Recurrence",
                "prediction": "Efficacy:Disease event",
                "score": 0.909725546836853,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "extensive metabolizer genotype (no null or reduced alleles)",
                "score": 0.864000678062439,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8673673629760742,
            "annotation": {
              "Variant/Haplotypes": "CYP2D6*1",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "Phenotype Category": "Efficacy",
              "Alleles": "*3/*3 + *4/*4",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Efficacy:Recurrence",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*1",
                "prediction": "CYP2D6*10",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "tamoxifen",
                "prediction": "tamoxifen",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*3/*3 + *4/*4",
                "prediction": "*10",
                "score": 0.8999474048614502,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Recurrence",
                "prediction": "Efficacy:Disease event",
                "score": 0.909725546836853,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "extensive metabolizer genotype (no null or reduced alleles)",
                "score": 0.864000678062439,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8669262826442719,
            "annotation": {
              "Variant/Haplotypes": "CYP2D6*1",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "Phenotype Category": "Efficacy",
              "Alleles": "*3/*3 + *4/*4",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Efficacy:Recurrence",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*1",
                "prediction": "CYP2D6*41",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "tamoxifen",
                "prediction": "tamoxifen",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*3/*3 + *4/*4",
                "prediction": "*41",
                "score": 0.8955366015434265,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Recurrence",
                "prediction": "Efficacy:Disease event",
                "score": 0.909725546836853,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": "extensive metabolizer genotype (no null or reduced alleles)",
                "score": 0.864000678062439,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6909725546836853,
            "annotation": {
              "Variant/Haplotypes": "CYP2D6*1",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "Phenotype Category": "Efficacy",
              "Alleles": "*3/*3 + *4/*4",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Efficacy:Recurrence",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*1",
                "prediction": "poor",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "tamoxifen",
                "prediction": "tamoxifen",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*3/*3 + *4/*4",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Recurrence",
                "prediction": "Efficacy:Disease event",
                "score": 0.909725546836853,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6909725546836853,
            "annotation": {
              "Variant/Haplotypes": "CYP2D6*1",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "Phenotype Category": "Efficacy",
              "Alleles": "*3/*3 + *4/*4",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Efficacy:Recurrence",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "*1/*1"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "CYP2D6*1",
                "prediction": "metabolizers",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "CYP2D6",
                "prediction": "CYP2D6",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "tamoxifen",
                "prediction": "tamoxifen",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Efficacy",
                "prediction": "efficacy",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "*3/*3 + *4/*4",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Efficacy:Recurrence",
                "prediction": "Efficacy:Disease event",
                "score": 0.909725546836853,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "*1/*1",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1444933987,
              "Variant/Haplotypes": "CYP2D6*1",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
              "Sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
              "Alleles": "*1/*10 + *1/*41 + *10/*10 + *41/*41",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Recurrence",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "1444933987",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1444933987,
              "Variant/Haplotypes": "CYP2D6*10",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
              "Sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
              "Alleles": "*1/*10 + *1/*41 + *10/*10 + *41/*41",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Recurrence",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "1444933987",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1444933987,
              "Variant/Haplotypes": "CYP2D6*41",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen",
              "PMID": 23213055,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "Genotyped for null alleles [*3 (2549 del A),*4(1846G>A), and *6(1707T>del)] reduced alleles [*10 (100 C>T and 1846 G>A) and *41 (2988 G>A)] with Applied Biosystems Taqman assay; duplicated alleles could not be assayed. \"extensive\" metabolizers do not carry a null or reduced allele (EM/EM); those with 1 to 2 reduced alleles without a null allele (EM/IM, IM/IM); one null allele (PM/IM, PM/EM), and \"poor\" metabolizers, those with 2 null alleles (PM/PM). Post-menopausal women with estrogen receptor positive breast cancer were treated 5 years with tamoxifen only. The study grouped cases (cancer recurrence) and controls (no recurrence). In a second study arm (tamoxifen+ anastrozole) the higher risk did not persist after switching to anastrozole. [postmenopausal] [adjuvant] [DNA source: paraffin-embedded tissue] [HWE: yes for *4, *6, *10; no for *3, *41]",
              "Sentence": "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.",
              "Alleles": "*1/*10 + *1/*41 + *10/*10 + *41/*41",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Recurrence",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in women with",
              "Population Phenotypes or diseases": "Disease:Breast Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1",
              "Comparison Metabolizer types": null,
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "1444933987",
              "_expanded_from_multi_variant": true
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 2,
        "items": [
          {
            "variant": "poor",
            "gene": "CYP2D6",
            "drug": "tamoxifen, anastrozole",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "poor",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen, anastrozole",
              "PMID": "23213055",
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In Arm B (2 years tamoxifen then anastrozole), PM/PM phenotype showed no significant association with disease events over 5 years (OR 0.60, 95% CI 0.15\u20132.37; p=0.47) compared with EM/EM.",
              "Sentence": "CYP2D6 poor metabolizers Are not associated with increased likelihood of a disease event when treated with tamoxifen and anastrozole in people with Disease:Breast Cancer.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Disease event",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "and",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Breast Cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Alleles or Genotype(s)": null,
              "Comparison Metabolizer types": "extensive metabolizer",
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "7",
              "Citations": [
                "Conversely in Arm B, no significant association was found between *CYP2D6* genotype and the likelihood of a disease event during the 5 years of treatment.",
                "During years 3\u20135, for women on Arm A who remained event free during the first 2 years of tamoxifen therapy, PM/PM (OR 2.40, 95% CI: 0.86 to 6.66, p = 0.09) and IM/PM or EM/PM (OR 1.70, 95% CI: 0.91\u20133.17, p=0.09) had a trend towards an increased odds of a disease event relative to EM/EM. In contrast, women on Arm B who remained event-free during the first 2 years of tamoxifen, the odds of disease event for PM/PM (OR 0.28, p = 0.23) and the IM/PM or EM/PM group (OR 0.63, p = 0.22) were found to be non-significantly decreased during years 3\u20135 relative to EM/EM.",
                "In summary, in the ABCSG 8 clinical trial, the CYP2D6 PM/PM phenotype was associated with a higher likelihood of an early disease event in women treated with 5 years of tamoxifen, but not in patients treated with sequential tamoxifen followed by anastrozole."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "poor metabolizers",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "anastrozole",
                "drug_id": "PA448432",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "metabolizers",
            "gene": "CYP2D6",
            "drug": "tamoxifen, anastrozole",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "metabolizers",
              "Gene": "CYP2D6",
              "Drug(s)": "tamoxifen, anastrozole",
              "PMID": "23213055",
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "In Arm B (2 years tamoxifen then anastrozole), PM/PM phenotype showed no significant association with disease events over 5 years (OR 0.60, 95% CI 0.15\u20132.37; p=0.47) compared with EM/EM.",
              "Sentence": "CYP2D6 poor metabolizers Are not associated with increased likelihood of a disease event when treated with tamoxifen and anastrozole in people with Disease:Breast Cancer.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": "likelihood of",
              "Phenotype": "Efficacy:Disease event",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "and",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Breast Cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Alleles or Genotype(s)": null,
              "Comparison Metabolizer types": "extensive metabolizer",
              "PMID_norm": "23213055",
              "Variant Annotation ID_norm": "7",
              "Citations": [
                "Conversely in Arm B, no significant association was found between *CYP2D6* genotype and the likelihood of a disease event during the 5 years of treatment.",
                "During years 3\u20135, for women on Arm A who remained event free during the first 2 years of tamoxifen therapy, PM/PM (OR 2.40, 95% CI: 0.86 to 6.66, p = 0.09) and IM/PM or EM/PM (OR 1.70, 95% CI: 0.91\u20133.17, p=0.09) had a trend towards an increased odds of a disease event relative to EM/EM. In contrast, women on Arm B who remained event-free during the first 2 years of tamoxifen, the odds of disease event for PM/PM (OR 0.28, p = 0.23) and the IM/PM or EM/PM group (OR 0.63, p = 0.22) were found to be non-significantly decreased during years 3\u20135 relative to EM/EM.",
                "In summary, in the ABCSG 8 clinical trial, the CYP2D6 PM/PM phenotype was associated with a higher likelihood of an early disease event in women treated with 5 years of tamoxifen, but not in patients treated with sequential tamoxifen followed by anastrozole."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "poor metabolizers",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "anastrozole",
                "drug_id": "PA448432",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          }
        ]
      }
    },
    "study_parameters": {
      "score": 0.7282368328836228,
      "total_samples": 3,
      "ground_truth_annotations": {
        "count": 3,
        "matched_count": 3,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.6426511687390944,
            "annotation": {
              "Study Parameters ID": 1444933961,
              "Variant Annotation ID": 1444933959,
              "Study Type": "prospective",
              "Study Cases": 166.0,
              "Study Controls": 287.0,
              "Characteristics": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); PM/IM and EM/PM vs EM/EM",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.07",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.67,
              "Confidence Interval Start": 0.95,
              "Confidence Interval Stop": 2.93,
              "Biogeographical Groups": "European"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1444933961,
                "prediction": 2,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1444933959,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "prospective",
                "prediction": "case/control",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 166.0,
                "prediction": 319,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": 287.0,
                "prediction": 557,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Characteristics": {
                "ground_truth": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); PM/IM and EM/PM vs EM/EM",
                "prediction": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 randomized to 5 years of tamoxifen (Arm A); association of CYP2D6 EM/PM or PM/IM phenotypes vs EM/EM with disease event during 5 years of tamoxifen therapy",
                "score": 0.9250698685646057,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.07",
                "prediction": "= 0.07",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 1.67,
                "prediction": 1.67,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 0.95,
                "prediction": 0.95,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 2.93,
                "prediction": 2.93,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6425851092619055,
            "annotation": {
              "Study Parameters ID": 1444933989,
              "Variant Annotation ID": 1444933987,
              "Study Type": "prospective",
              "Study Cases": 166.0,
              "Study Controls": 287.0,
              "Characteristics": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); IM/IM and EM/IM vs EM/EM",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.6",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.23,
              "Confidence Interval Start": 0.58,
              "Confidence Interval Stop": 2.61,
              "Biogeographical Groups": "European"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1444933989,
                "prediction": 3,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1444933987,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "prospective",
                "prediction": "case/control",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 166.0,
                "prediction": 319,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": 287.0,
                "prediction": 557,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Characteristics": {
                "ground_truth": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); IM/IM and EM/IM vs EM/EM",
                "prediction": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 randomized to 5 years of tamoxifen (Arm A); association of CYP2D6 EM/IM or IM/IM phenotypes vs EM/EM with disease event during 5 years of tamoxifen therapy",
                "score": 0.9239468574523926,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.6",
                "prediction": "= 0.60",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 1.23,
                "prediction": 1.23,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 0.58,
                "prediction": 0.58,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 2.61,
                "prediction": 2.61,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.6424494561027078,
            "annotation": {
              "Study Parameters ID": 1444933951,
              "Variant Annotation ID": 1444933926,
              "Study Type": "prospective",
              "Study Cases": 166.0,
              "Study Controls": 287.0,
              "Characteristics": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); PM/PM vs EM/EM",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.04",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.45,
              "Confidence Interval Start": 1.05,
              "Confidence Interval Stop": 5.73,
              "Biogeographical Groups": "European"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1444933951,
                "prediction": 1,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1444933926,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "prospective",
                "prediction": "case/control",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 166.0,
                "prediction": 319,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Controls": {
                "ground_truth": 287.0,
                "prediction": 557,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Characteristics": {
                "ground_truth": "endpoint: event (disease recurrence, contralateral breast cancer, second non-breast cancer, or death); PM/PM vs EM/EM",
                "prediction": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 randomized to 5 years of tamoxifen (Arm A); association of CYP2D6 PM/PM phenotype vs EM/EM with disease event during 5 years of tamoxifen therapy",
                "score": 0.9216407537460327,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "drug",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.04",
                "prediction": "= 0.04",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "OR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.45,
                "prediction": 2.45,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.05,
                "prediction": 1.05,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 5.73,
                "prediction": 5.73,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European",
                "score": 1.0,
                "match_status": "match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 7,
        "items": [
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 4,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 319,
              "Study Controls": 557,
              "Characteristics": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 randomized to 2 years of tamoxifen followed by 3 years of anastrozole (Arm B); association of CYP2D6 PM/PM phenotype vs EM/EM with disease event during 5 years of sequential therapy",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.47",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.6,
              "Confidence Interval Start": 0.15,
              "Confidence Interval Stop": 2.37,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 5,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 319,
              "Study Controls": 557,
              "Characteristics": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 randomized to 2 years of tamoxifen followed by 3 years of anastrozole (Arm B); association of CYP2D6 EM/PM or PM/IM phenotypes vs EM/EM with disease event during 5 years of sequential therapy",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.32",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.76,
              "Confidence Interval Start": 0.43,
              "Confidence Interval Stop": 1.31,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 6,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 319,
              "Study Controls": 557,
              "Characteristics": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 randomized to 2 years of tamoxifen followed by 3 years of anastrozole (Arm B); association of CYP2D6 EM/IM or IM/IM phenotypes vs EM/EM with disease event during 5 years of sequential therapy",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.96",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.02,
              "Confidence Interval Start": 0.52,
              "Confidence Interval Stop": 2.01,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 7,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 319,
              "Study Controls": 557,
              "Characteristics": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 Arm A; CYP2D6 PM/PM vs EM/EM and odds of disease event during years 3\u20135 while continuing tamoxifen (among women event-free in first 2 years)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.09",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 2.4,
              "Confidence Interval Start": 0.86,
              "Confidence Interval Stop": 6.66,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 8,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 319,
              "Study Controls": 557,
              "Characteristics": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 Arm A; CYP2D6 EM/PM or PM/IM vs EM/EM and odds of disease event during years 3\u20135 while continuing tamoxifen (among women event-free in first 2 years)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.09",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 1.7,
              "Confidence Interval Start": 0.91,
              "Confidence Interval Stop": 3.17,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 9,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 319,
              "Study Controls": 557,
              "Characteristics": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 Arm B; CYP2D6 PM/PM vs EM/EM and odds of disease event during years 3\u20135 while on anastrozole after 2 years of tamoxifen (among women event-free in first 2 years)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.23",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.28,
              "Confidence Interval Start": 0.03,
              "Confidence Interval Stop": 2.3,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 10,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 319,
              "Study Controls": 557,
              "Characteristics": "Postmenopausal Austrian women with estrogen receptor\u2013positive early breast cancer in ABCSG-8 Arm B; CYP2D6 EM/PM or PM/IM vs EM/EM and odds of disease event during years 3\u20135 while on anastrozole after 2 years of tamoxifen (among women event-free in first 2 years)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.22",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.63,
              "Confidence Interval Start": 0.31,
              "Confidence Interval Stop": 1.28,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          }
        ]
      }
    }
  }
}